Equity Profile

ARQT

Arcutis Biotherapeutics, Inc.

Health CareBiotechnology$2.7B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) is a biotechnology company focused on developing innovative treatments for skin diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will show how well the company is managing its costs relative to its revenue.

N/A

Revenue Growth

Revenue growth is critical for assessing the company's ability to expand its market presence and validate its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ARQT Q2-2026 Earnings Preview

Context

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) is a biotechnology company focused on developing innovative treatments for skin diseases. With a market cap of $3 billion, it operates in the healthcare sector, aiming to address unmet needs in dermatology, which is increasingly important as skin conditions affect millions globally.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.67%

Avg Stock Reaction

+2.77%

Last Quarter Recap

In Q1-2026, Arcutis reported an EPS of -$0.09, missing expectations by a significant margin. Despite this, the stock rose by 3.20% the following day, reflecting some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Arcutis are mixed, with investors keenly watching for any signs of revenue growth and updates on its product pipeline. The company's ability to deliver positive surprises has historically led to stock price increases.

Bull Case

If Arcutis can demonstrate strong revenue growth and positive updates on its product pipeline, it could significantly boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet expectations again or provides disappointing updates on its products, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for the upcoming quarter?

Revenue growth will be a crucial indicator of the company's market performance and its ability to attract and retain customers.

Are there any updates on the product pipeline and upcoming clinical trials?

Updates on the product pipeline can significantly impact investor sentiment and the company's future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Arcutis's product pipeline to deliver unexpected results, especially given recent positive trends in dermatology treatments.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with an 88% beat rate historically.

Options pricing suggests a significant move, indicating that investors are anticipating volatility that may not align with current consensus.

Recent insider trading activity, although limited, suggests some level of confidence in the company's future prospects.

Key Risk

If revenue growth exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Arcutis can translate its innovative pipeline into tangible revenue growth.

Bull Confirmed If

A revenue growth of over 15% quarter-over-quarter would confirm the bull case.

Bear Confirmed If

A revenue decline or no growth would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±18.36%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±18.4% while ARQT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

62.0%

Calls (13K)P/C Ratio: 0.14Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcutis beats expectations, history suggests a potential average stock move of +2.70%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline, with history suggesting an average move of +3.20% in the event of disappointing results.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific revenue growth figures for the upcoming quarter.
2Updates on clinical trials and product pipeline developments.
3Management's commentary on market conditions and competitive landscape.
4Insights into cost management and operational efficiency.
5Any changes in guidance or future outlook.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) is a biotechnology company focused on developing innovative treatments for skin diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will show how well the company is managing its costs relative to its revenue.

N/A

Revenue Growth

Revenue growth is critical for assessing the company's ability to expand its market presence and validate its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ARQT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.67%

Avg Stock Reaction

+2.77%

Last Quarter Recap

In Q1-2026, Arcutis reported an EPS of -$0.09, missing expectations by a significant margin. Despite this, the stock rose by 3.20% the following day, reflecting some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Arcutis can demonstrate strong revenue growth and positive updates on its product pipeline, it could significantly boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet expectations again or provides disappointing updates on its products, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for the upcoming quarter?

Revenue growth will be a crucial indicator of the company's market performance and its ability to attract and retain customers.

Are there any updates on the product pipeline and upcoming clinical trials?

Updates on the product pipeline can significantly impact investor sentiment and the company's future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Arcutis's product pipeline to deliver unexpected results, especially given recent positive trends in dermatology treatments.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with an 88% beat rate historically.

Options pricing suggests a significant move, indicating that investors are anticipating volatility that may not align with current consensus.

Recent insider trading activity, although limited, suggests some level of confidence in the company's future prospects.

Key Risk

If revenue growth exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Arcutis can translate its innovative pipeline into tangible revenue growth.

Bull Confirmed If

A revenue growth of over 15% quarter-over-quarter would confirm the bull case.

Bear Confirmed If

A revenue decline or no growth would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±18.36%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±18.4% while ARQT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

62.0%

Calls (13K)P/C Ratio: 0.14Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcutis beats expectations, history suggests a potential average stock move of +2.70%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline, with history suggesting an average move of +3.20% in the event of disappointing results.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific revenue growth figures for the upcoming quarter.
2Updates on clinical trials and product pipeline developments.
3Management's commentary on market conditions and competitive landscape.
4Insights into cost management and operational efficiency.
5Any changes in guidance or future outlook.